PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group - 03/01/24

Doi : 10.1016/S1470-2045(23)00525-9

Nathalie L Albert, ProfMD ^a, Norbert Galldiks, ProfMD ^c,^d,^e, Benjamin M Ellingson, ProfPhD ^f, Martin J van den Bent, ProfMD ^g, Susan M Chang, ProfMD ^h, Francesco Cicone, ProfMD PhD ⁱ, John de Groot, ProfMD ^h, Eng-Siew Koh, ProfMD ^j,^k, Ian Law, ProfMD PhD ^l, Emilie Le Rhun, ProfMD PhD ^m,ⁿ, Maximilian J Mair, MD PhD ^p, Giuseppe Minniti, ProfMD PhD ^q,^r, Roberta Rudà, ProfMD ^s, Andrew M Scott, ProfMD ^t,^u, Susan C Short, ProfMD PhD ^v, Marion Smits, ProfMD PhD ^w,^x,^y, Bogdana Suchorska, MD ^z, Nelleke Tolboom, MD PhD ^aa, Tatjana Traub-Weidinger, MD ^ab, Joerg-Christian Tonn, ProfMD ^b, Antoine Verger, ProfMD PhD ^ac, Michael Weller, ProfMD ^n,^o, Patrick Y Wen, ProfMD ^ad, Matthias Preusser, ProfMD ^p,⁎

^a Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany

^b Department of Neurosurgery, LMU Hospital, LMU Munich, Munich, Germany

^c Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

^d Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany

^e Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany

^f UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

^g The Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, Netherlands

^h Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA

ⁱ Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy

^j Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centre, Liverpool, NSW, Australia

^k South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia

^l Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark

^m Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland

ⁿ Department of Neurology, University Hospital Zurich, Zurich, Switzerland

^o Department of Neurology, University of Zurich, Zurich, Switzerland

^p Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

^q Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy

^r IRCCS Neuromed, Pozzilli IS, Italy

^s Division of Neuro-Oncology, Department of Neuroscience, University of Turin and City of Health and Science of Turin, Turin, Italy

^t Department of Molecular Imaging and Therapy, Austin Health and University of Melbourne, Melbourne, VIC, Australia

^u Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia

^v Leeds Institute of Medical Research at St James’s, The University of Leeds, Leeds, UK

^w Department of Radiology & Nuclear Medicine, Erasmus MC–University Medical Centre Rotterdam, Rotterdam, Netherlands

^x Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands

^y Medical Delta, Delft, Netherlands

^z Department of Neurosurgery, Heidelberg University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany

^aa Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands

^ab Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

^ac Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Universitè de Lorraine, Nancy, France

^ad Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

^* Correspondence to: Prof Matthias Preusser, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna 1090, Austria Division of Oncology Department of Medicine I Medical University of Vienna Vienna 1090 Austria

Summary

Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

The process of developing PET RANO 1.0

Method of measurements

Imaging technology

Tracers

Rater qualification and training

Two-dimensional versus volumetric assessment

Relation to MRI-based and clinical response assessment

Implementation in clinical trials

Definitions

PET parameters

Measurable and non-measurable disease

Target lesions

Baseline PET

Follow-up schedule in clinical trials

PET-based response and progression

Key recommendations for future research

Conclusion

Search strategy and selection criteria

Export

Vol 25 - N° 1

P. e29-e41 - janvier 2024 Retour au numéro

Article précédent

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)
Shankar Siva, Alexander V Louie, Rupesh Kotecha, Melissa N Barber, Muhammad Ali, Zhenwei Zhang, Matthias Guckenberger, Mi-Sook Kim, Marta Scorsetti, Alison C Tree, Ben J Slotman, Arjun Sahgal, Simon S Lo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group - 03/01/24

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL